How Much Does Wegovy Cost in 2026

Wegovy costs $1,349.02 at list price and $349 or less through NovoCare self-pay

Novo Nordisk publishes one list price, $1,349.02 per package, for the Wegovy pen, the Wegovy HD pen, and the Wegovy pill. A package is one box of four single-dose pens, which the pharmacy terms treat as a 28-day supply, or one bottle of 30 tablets. That figure is the wholesale acquisition cost, the number insurers, pharmacy benefit managers, and pharmacies negotiate from. It is what a pharmacy would charge someone with no coverage, no savings card, and no manufacturer program.

The price a person actually pays depends on which of four paths they qualify for. Self-pay patients buy through NovoCare Pharmacy at fixed monthly prices. Commercially insured patients whose plan covers Wegovy use the savings card. Eligible Medicare Part D beneficiaries use the GLP-1 Bridge. Everyone else pays whatever their plan's copay or coinsurance works out to, which can land anywhere between the savings-card floor and the list price. The table sorts the four paths by what they require and what they cost on the day this article was checked.

What the 0.25 mg starter pen and every other dose cost through NovoCare Pharmacy

The Wegovy label starts injection treatment at 0.25 mg once weekly for weeks 1 through 4, then 0.5 mg for weeks 5 through 8, 1 mg for weeks 9 through 12, and 1.7 mg for weeks 13 through 16 before a maintenance dose. Pens come in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, and 7.2 mg strengths. Tablets come in 1.5 mg, 4 mg, 9 mg, and 25 mg. Because NovoCare prices by dose, the answer to how much the 0.25 mg pen costs is different from the answer for a maintenance pen.

For new self-pay patients, NovoCare Pharmacy charges $199 for each of the first two monthly fills of the 0.25 mg or 0.5 mg pen, as long as the prescription is written on or before December 31, 2026. After those two fills, the 1 mg, 1.7 mg, and 2.4 mg pens cost $349 a month and the 7.2 mg Wegovy HD pen costs $399 a month. The pharmacy terms also list multi-month totals of $698 for two months and $1,047 for three months at the $349 rate. Home delivery is free, and a valid prescription from a licensed prescriber is required before anything ships.

The pill follows its own schedule. The 1.5 mg tablet is $149 a month, the 4 mg tablet is $199 a month, and the 9 mg and 25 mg tablets are $299 a month, with one month defined as a bottle of 30 tablets. A limited-time $149 price on the 4 mg tablet applied only to prescriptions written on or before August 31, 2026 and has expired. Novo Nordisk states that all of these offers can be modified or cancelled at any time and that self-pay pricing is scheduled to be updated after December 31, 2026.

The $25 savings card lowers the price only when commercial insurance already covers Wegovy

The Wegovy savings offer lets commercially insured patients pay as little as $25 a month for the pen or the pill. The card works by paying part of the copay after the plan pays its share, and Novo Nordisk caps that contribution at $100 a month. If a plan covers Wegovy with a $125 copay, the card brings it to $25. If the plan requires a $600 copay, or has not met a deductible, the card still removes only $100 and the patient pays $500. The card is a copay reducer, not a price.

People enrolled in Medicare, Medicaid, or other government, state, or federally funded medical or prescription benefit programs are excluded from the card. Novo Nordisk states they can instead choose the self-pay price through NovoCare Pharmacy, which processes outside insurance. The terms add that Federal Employees Health Benefits plans, Affordable Care Act plans, and state employee plans are not treated as government programs for this offer. The current terms run through December 31, 2026, after which Novo Nordisk says pricing will be updated.

A plan that lists Wegovy on its formulary has not necessarily approved a claim. Prior authorization, step therapy, a BMI or comorbidity requirement, and a specific pharmacy network can all sit between a formulary listing and a $25 fill. The GLP-1 insurance coverage guide linked below walks through the questions that turn a formulary listing into a usable price.

Medicare Part D does not routinely cover Wegovy for weight loss, and the Bridge is the exception

Medicare.gov states that Part D plans do not routinely cover GLP-1 drugs for weight loss. Part D can cover semaglutide products when the prescription is for a Part D-coverable indication, and CMS lists type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis as examples. A prescription written for weight management alone falls outside ordinary Part D coverage.

The Medicare GLP-1 Bridge is a temporary CMS demonstration that fills part of that gap from July 1, 2026 through December 31, 2027. Eligible Part D beneficiaries pay a $50 copay for a 28- or 30-day supply of Wegovy injection or tablets, Foundayo tablets, or the Zepbound KwikPen. Eligibility runs through a central prior authorization with CMS clinical criteria, and the $50 does not count toward the Part D deductible or the yearly out-of-pocket limit. Beneficiaries already getting a GLP-1 covered through their Part D plan are not eligible for the Bridge.

Two consequences follow for cost planning. A Medicare beneficiary who qualifies for the Bridge pays less per month than any NovoCare self-pay price. A Medicare beneficiary who does not qualify cannot use the commercial savings card either, which leaves the $199 then $349 self-pay path or the list price. Read the current CMS criteria before assuming either outcome.

Telehealth companies prescribe Wegovy; they do not discount it

A telehealth weight-loss company is a medical practice, sometimes with a pharmacy partner. Its clinicians evaluate a patient, write the Wegovy prescription, and route it to a pharmacy. The pharmacy, or NovoCare Pharmacy if the prescription goes there, charges the drug price. No telehealth company sets the price of Wegovy, and none of the providers in the Telehealth Ledger catalog publish a Wegovy medication price below the NovoCare self-pay price.

That is why the Wegovy program page shows figures that look like they cannot describe the same product. One provider publishes a monthly price that pays for the consultation only, with the medication billed separately at the pharmacy. Others publish a monthly price that includes the drug, and those figures sit at roughly the $1,349.02 list price or above it, because the provider is passing through a pharmacy charge without a manufacturer program. The live module on this page reads the same catalog and labels each row as medication-included or consultation-only, with the date each price was verified.

The useful question for a telehealth quote is therefore not whether it is cheaper than Wegovy. It is what the fee buys. A consultation-only fee is worth paying when the patient has coverage, a savings card, Bridge eligibility, or a NovoCare self-pay plan and needs a prescriber. A medication-included fee is worth comparing against the NovoCare self-pay price for the same dose, and it rarely wins on price alone.

Wegovy versus compounded semaglutide: a different product with a different price structure

Compounded semaglutide is not Wegovy. FDA states that compounded drugs are not FDA approved and that the agency does not review them for safety, effectiveness, or quality before they are marketed. FDA also says a compounded drug might be appropriate only when a patient's medical need cannot be met by an approved drug or the approved drug is not commercially available. Semaglutide came off the FDA drug shortage list in February 2025, and FDA's April 2026 clarification restricts compounders from regularly producing copies of commercially available approved drugs.

The price structure differs as much as the regulatory status. Wegovy has one manufacturer list price, a published self-pay schedule by dose, a savings card, and a Medicare demonstration. Compounded semaglutide has none of those. Each telehealth company sets its own bundled monthly price with its own compounding pharmacy, and that price usually includes the clinician visit, the vial or pen, and shipping. Because there is no list price, there is also no insurance negotiation, no manufacturer copay support, and no Bridge copay.

Comparing the two on price means comparing a NovoCare self-pay figure for a specific Wegovy dose against a program fee for a product with a different formulation, concentration, and legal basis. The compounded semaglutide program page lists current provider prices with their commitment terms and pharmacy disclosures. Use it to see what compounded programs charge, and use the clinical questions in the compounded GLP-1 guide to decide whether an approved product meets the need first.

Do not treat a compounded semaglutide program as a lower-priced version of Wegovy. The product, pharmacy, and regulatory status differ, and the prescribing clinician and dispensing pharmacy must resolve whether compounding is appropriate.

What a year of Wegovy costs on each path

Annual arithmetic exposes the difference between the paths. A new self-pay patient who starts on the 0.25 mg pen, moves through the labeled escalation, and stays on a standard pen dose pays $199 for two fills and $349 for ten, a total of $3,888 for twelve monthly fills, assuming the prescription is written before the December 31, 2026 cutoff and Novo Nordisk holds the continuing price. A patient who reaches the 7.2 mg Wegovy HD pen pays $399 for those months instead. A patient on the 25 mg pill pays $299 a month, or $3,588 for twelve bottles.

A commercially insured patient whose plan covers Wegovy and whose copay is at most $125 pays $25 a month with the savings card, or $300 a year, until the offer terms change after December 31, 2026. A patient whose plan does not cover Wegovy is back on the self-pay schedule. An eligible Medicare beneficiary pays $50 a month through the Bridge, or $600 a year, through December 31, 2027. Someone paying list price with no program pays $1,349.02 per package, or $16,188.24 for twelve packages.

Three costs sit outside these totals. A telehealth or in-person consultation fee applies whenever the prescriber charges one. Laboratory work, if the clinician orders it, is billed separately. And the escalation schedule itself can change the total, because a clinician may hold a patient at a lower dose or move to a higher one, and each move changes which NovoCare price applies. Recheck the current NovoCare page before each refill rather than relying on a price from a prior month.